cort 108297
Small moleculeexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Jun 28, 2021 (NCT04601038)
Timeline
2020s
- Jan 1, 2021
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
- Glucocorticoid receptorANTAGONIST
NR3C1 antagonist
Company reports initiation of No Ph1 trial in 2010 but no ID found and no further trials planned. Discontinuedcompound?
Chemistry & pharmacology
Loading structure…
SMILES
CCOC[C@]12Cc3cnn(-c4ccc(F)cc4)c3C=C1CCN(S(=O)(=O)c1ccc(C(F)(F)F)cc1)C2- Mol. weight
- 535.56 g/mol
- Lipinski Ro5
- 2 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL271220 ↗
Also known as
- cort 108297
- cort 108297
- cort-108297
- cort-108297
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04452500 | Phase 2 | Jan 3, 2022 | Department of Veteran Affairs |
| NCT04601038 | Phase 2 | Jun 28, 2021 | Johns Hopkins University |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Department of Veteran Affairs | Government | 1 | 1 | 1 | 2022 |
| Johns Hopkins University | Academic/Hospital | 1 | 1 | 1 | 2021 |
2 organizations
Page 1 / 1